

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 17, 2020

Global Blood Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation)

001-37539
(Commission File Number)

27-4825712
(I.R.S. Employer Identification Number)

181 Oyster Point Blvd.
South San Francisco, CA 94080
(Address of principal executive offices, including zip code)

(650) 741-7700
(Registrant's telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.001 per share	GBT	The NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.07 Submission of Matters to a Vote of Security Holders.

The proposals set forth below were submitted to the stockholders at the 2020 Annual Meeting of Stockholders, or Annual Meeting, of Global Blood Therapeutics, Inc., or Company, held on June 17, 2020, with each such proposal described in the Company's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 28, 2020, or Proxy Statement.

The number of shares of common stock entitled to vote at the Annual Meeting was 60,915,556. The number of shares of common stock present or represented by valid proxy at the Annual Meeting was 49,911,876. The number of votes cast for and against and the number of abstentions and broker non-votes with respect to each proposal voted upon are set forth below.

Proposal 1 – Election of Directors

The Company's stockholders elected the Class II director nominees below to the Company's Board of Directors to hold office until the 2023 Annual Meeting of Stockholders or until their successors are duly elected and qualified.

Director Nominee	Votes For	Votes Withheld
Willie L. Brown, Jr.	35,025,579	9,883,586
Philip A. Pizzo, M.D.	35,335,994	9,573,171
Wendy Yarno	35,294,219	9,614,946

There were 5,002,711 broker non-votes regarding this proposal.

Proposal 2 – Approval, on a Non-Binding, Advisory Basis, of the Compensation of the Company's Named Executive Officers as Disclosed in the Proxy Statement

The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.

Votes For	Votes Against	Abstentions
34,679,603	10,066,380	163,182

There were 5,002,711 broker non-votes regarding this proposal.

Proposal 3 – Ratification of Appointment of Independent Registered Accounting Firm

The Company's stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2020.

Votes For	Votes Against	Abstentions
49,805,133	70,394	36,349

There were no broker non-votes regarding this proposal.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Global Blood Therapeutics, Inc.

Date: June 19, 2020

By: /s/ Jeffrey Farrow
Jeffrey Farrow
Chief Financial Officer
(Principal Financial Officer)